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Computer-assisted simulation is a promising approach for clarifying complicated signaling networks.However, this approach is cur-
rently limited by a deficiency of kinetic parameters determined in living cells. To overcome this problem,we applied fluorescence
cross-correlation spectrometry (FCCS) tomeasure dissociation constant (Kd) values of signalingmolecule complexes in living cells (in
vivoKd). Among the pairs of fluorescentmolecules tested, that ofmonomerized enhanced green fluorescent protein (mEGFP) and
HaloTag-tetramethylrhodaminewasmost suitable for themeasurement of in vivo Kd by FCCS. Using this pair, we determined 22 in
vivo Kd values of signalingmolecule complexes comprising the epidermal growth factor receptor (EGFR)–Ras–extracellular signal-
regulated kinase (ERK)mitogen-activated protein (MAP) kinase pathway.With these parameters, we developed a kinetic simulation
model of the EGFR-Ras-ERKMAPkinase pathway anduncovered a potential role played by stoichiometry in Shc binding to EGFR
during the peak activations of Ras,MEK, and ERK. Intriguingly,most of the in vivo Kd values determined in this studywere higher
than the in vitro Kd values reported previously, suggesting the significance of competitive bindings inside cells. These in vivo Kd values
will provide a soundbasis for the quantitative understanding of signal transduction.
The epidermal growth factor (EGF) receptor (EGFR)–Ras– ex-tracellular signal-regulated kinase (ERK) mitogen-activated
protein (MAP) kinase pathway plays pleiotropic roles in cell func-
tions such as cell proliferation, differentiation, survival, and tu-
morigenesis (1–3). This signaling pathway has been extensively
studied, and vast amounts of proteins and regulations have been
identified, resulting in an increase in the pathway’s complexity.
Computer-assisted simulation is one of the most promising ap-
proaches for the comprehensive understanding of the signal
transduction pathway as a system. Indeed, a number of simulation
models of the EGFR-Ras-ERK MAP kinase pathway have been
reported over the past 10 years (4–7). In these simulation models,
most of the kinetic parameters used for numerical simulations
were not measured experimentally but rather were assumed by
fitting the experimental data with the simulation data or simply
determined arbitrarily. Consequently, there are substantial differ-
ences in the parameters among these studies, making it difficult to
evaluate these simulation models quantitatively.
The kinetic parameters used for the simulation of intracellular
signal transduction include protein concentrations, enzymatic ki-
netics, diffusion coefficients, and dissociation constants of the
protein-protein interactions, which are denotedKd. Among them,
Kd is of central importance, because protein-protein interactions
are a major constituent of signal transduction pathways (8). Un-
der steady-state conditions, the Kd of the simple binding between













where kf and kb are association and dissociation rate constants,
respectively, and [Free A], [Free B], and [AB] correspond to the
concentrations of unbound free protein A, protein B, and protein
AB complexes, respectively. According to these definitions, the
smaller theKd values, the higher the affinity of the protein-protein
interaction.
TheKd value has been determined by in vitro experiments such
as coprecipitation experiments, sedimentation equilibrium using
analytical ultracentrifugation, surface plasmon resonance (SPR),
and isothermal titration calorimetry (ITC). All of these in vitro
methods enable us to acquire the Kd value (here referred to as the
“in vitro Kd” value) (Fig. 1A). The in vitro Kd value reflects the
strength of the protein-protein interaction determined by the in-
trinsic properties of the two proteins. On the other hand, a few
reports have measured dissociation constants in living cells (here
referred to as the “in vivo Kd”) (Fig. 1B) by means of intermolec-
ular fluorescence resonance energy transfer (FRET), single-mole-
cule fluorescence imaging, and fluorescence cross-correlation
spectroscopy (FCCS) (9–12). All of these techniques employ two-
color fluorescence imaging. Theoretically, the in vivo Kd can be
affected mainly by two factors: competitive binding and molecular
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crowding (Fig. 1B). In the former case, non-fluorescently labeled
proteins, including endogenous and other interacting proteins,
bind competitively to fluorescently labeled molecules and conse-
quently appear to lead to an overestimation of the in vivo Kd values
relative to the in vitro Kd values (Fig. 1B, top). The overestimated
Kd is also known as the “apparent Kd.” Meanwhile, in the latter
case, macromolecular crowding can occur because the cytosol
contains numerous molecular species, such as proteins, lipids, and
nucleotides, and so on, which occupy a substantial fraction of the
volume within the cytoplasm (13). Such molecular crowding can
profoundly influence protein-protein binding through an exclud-
ed-volume effect (14, 15) (Fig. 1B, bottom). The in vivo Kd confers
a potential advantage to kinetic simulation models, because the in
vivo Kd authentically includes the effects of all intracellular envi-
ronments, such as competitive bindings and molecular crowding,
on protein-protein interactions within a cell. However, to date,
only a few in vivo Kd values have been made available for computer
simulation for the EGFR-Ras-ERK MAP kinase pathway, possibly
due to the technical difficulties.
FCCS allows the measurement of protein mobility, protein
concentrations, and protein-protein interactions by exploiting
the temporal fluorescence fluctuations of two diffusing fluores-
cently labeled particles under a confocal laser scanning micro-
scope with a tiny focal volume, called the effective volume (16). As
a distinct number of fluorescently labeled molecules diffuse
through the effective volume (approximately 1 fl), the fluores-
cence signals fluctuate in a manner dependent on the mobility and
concentration. An autocorrelation function of the fluctuating flu-
orescence signal provides the diffusion coefficient and concentra-
tion of molecules. FCCS utilizes two spectrally different fluoro-
phores to label a pair of proteins. If the differently labeled particles
are associated with each other, they pass through the effective
volume in a synchronized way. Therefore, the simultaneous fluc-
tuations of their fluorescence signals lead to an increase in the
amplitude of the cross-correlation function. The amplitude pro-
vides the concentration of the protein-protein complex.
In this study, we established a method for obtaining in vivo Kd
values in living cells by FCCS and determined20 in vivo Kd values
for the EGFR-Ras-ERK MAP kinase pathway in HeLa cells. In addi-
tion, we built a simulation model of the EGFR-Ras-ERK MAP kinase
pathway based on the in vivo Kd values. This model suggested that
multiple bindings of Shc to phosphorylated EGFR (pEGFR) are re-
quired for the peak activation of Ras, MEK, and ERK in response to
EGF stimulation. Intriguingly, most of the in vivoKd values measured
in this study were higher than those measured previously by in vitro
experiments, suggesting that competitive bindings play a major role
in the in vivo Kd values within the cytoplasm.
MATERIALS AND METHODS
Plasmids.The cDNA of HaloTag was amplified by PCR using the pFC14A
(HaloTag 7) cytomegalovirus (CMV) Flexi vector (Promega, Madison,
WI) as the template. The cDNA of monomerized enhanced green fluores-
cent protein (mEGFP), HaloTag, or the GGSGGS linker was inserted
into the pCAGGS, pCXN2, pCX4puro, or pCX4neo vector (17, 18)
to generate pCAGGS-HaloTag-GGSGGS-mEGFP, pCAGGS-mEGFP,
pCAGGS-FLAG-mEGFP, pCXN2-mEGFP, pCX4puro-HaloTag,
pCX4neo-mEGFP, pCAGGS-FLAG-HaloTag, and pCXN2-HaloTag.
pDONR223-RPS6KA1 (RSK1), pDONR223-RPS6KA2 (RSK3), and
pDONR223-KSR (KSR1) were gifts from William Hahn (19)
(Addgene plasmids 23860, 23530, and 23443, respectively). The cDNAs of
human RSK1 and human RSK3 were amplified by PCR. The cDNAs of
human Shc1 (20), human Grb2 (21), mouse Sos1 (22), mouse p85, cow
p110 (23), human HRasdCT-G12V (where dCT stands for deleted C
terminus) (24), human BRaf, human BRaf-S364A (25), human CRaf, hu-
man CRaf-S259A (24), human RSK2 (26), human RSK1, and human

















































































































FIG 1 Strategy for measuring in vivo Kd by FCCS. (A and B) Comparison
between in vitro Kd (A) and in vivo Kd (B) values. In general, the in vivo Kd was
affected by competitive binding proteins (B, top) and molecular crowding (B,
bottom), leading to increased and decreased of Kd values compared to the in
vitro Kd values (A), respectively. (C) Experimental procedure for measurement
of in vivo Kd by FCCS. HeLa cells were cotransfected with two plasmids ex-
pressing fluorescent protein-fused proteins A and B. Two days after transfec-
tion, the cells were subjected to FCCS measurements. At least 5 points in the
cytoplasm of each cell were analyzed by FCCS. In each cell, the concentra-
tions of total A protein ([Atotal]), total B protein ([Btotal]), and the protein
AB complex ([AB]) were obtained by the y intercepts of the autocorrelation
curves (red and green curves) and cross-correlation curve (blue curve),
respectively. The averaged values of the ratios of [AB] to [Btotal] in each cell,
with standard deviations, are plotted against the unbound A protein con-
centration ([Atotal]  [AB]), with standard deviations. The Kd value was
obtained by fitting the data to equations 16 and 17.
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loTag-RSK1, pCXN2-HaloTag-RSK2, and pCXN2-HaloTag-RSK3,
respectively. Human MEK1, human MEK2, human ERK1, and human ERK2
were obtained by reverse transcription-PCR (RT-PCR) with a HeLa cDNA
library and subcloned into the mEGFP or HaloTag vector to generate
pCAGGS-FLAG-MEK1-HaloTag, pCAGGS-FLAG-MEK2-HaloTag,
pCXN2-mEGFP-ERK1, and pCXN2-mEGFP-ERK2, respectively. The ccdB
gene and chloramphenicol resistance genes sandwiched with aatR1 and aatR2
were amplified by PCR and inserted into the pCAGGS-mEGFP vector.
pCAGGS-mEGFP-KSR1 was constructed with pCAGGS-mEGFP-ccdB and
pDONR223-KSR by using the Gateway vector conversion system according
to the manufacturer’s instructions (Invitrogen, San Diego, CA). The cDNA of
human EGFR was subcloned into the pPBbsr2-mEGFP vector to generate
pPBbsr2-EGFR-mEGFP (27).
Cells, reagents, and antibodies. HeLa cells were purchased from the
Human Science Research Resources Bank (Sennanshi, Japan) and main-
tained in Dulbecco’s modified Eagle medium (DMEM) (Sigma-Aldrich,
St. Louis, MO) supplemented with 10% fetal bovine serum (FBS). HeLa
cells stably expressing mEGFP, HaloTag, or both HaloTag-Shc and EGFR-
mEGFP were established in accordance with the conventional retroviral
gene transfer and piggyBac transposon systems (17, 28). EGF and sodium
orthovanadate (Na3VO4) were purchased from Sigma-Aldrich. Tetradec-
anoyl phorbol acetate (TPA) was purchased from Calbiochem (La Jolla,
CA). HaloTag-TMR (tetramethylrhodamine) ligand and anti-HaloTag
antibody (G9281) were purchased from Promega. The following antibod-
ies were also used in this study: anti-Grb2 (catalog number sc-255), anti-
RSK1 (catalog number sc-231), anti-RSK2 (catalog number sc-9986), and
anti-RSK3 (catalog number sc-1431) antibodies (purchased from Santa
Cruz Biotechnology, Santa Cruz, CA); anti-Shc (catalog number 610879),
anti-MEK1 (catalog number 610121), and anti-MEK2 (catalog number
610235) antibodies (BD Transduction Laboratories, San Jose, CA); anti-
green fluorescent protein (GFP) (catalog number 632375) antibody
(Clontech, Palo Alto, CA); and anti-p44/p42 MAP kinase (ERK1/2) anti-
body (catalog number 4695; Cell Signaling Technology, Danvers, MA).
PD-184352 was purchased from Toronto Research Chemicals (Toronto,
Canada).
FCCS measurements. HeLa cells were plated onto 35-mm glass-base
dishes (Asahi Techno Glass, Tokyo, Japan). One day after plating, plas-
mids were transfected by using 293fectin transfection reagent according
to the manufacturer’s instructions (Invitrogen, San Diego, CA). Two or
three days after transfection, the cells were labeled with HaloTag-TMR
ligand, as described below.
FCCS measurements were performed with the LSM780 Meta/Confo-
Cor 2 system (Carl Zeiss, Oberkochen, Germany) and the FV-1000 con-
focal imaging system (Olympus, Tokyo, Japan), equipped with gallium
arsenide phosphide (GaAsP) detectors. With respect to the Zeiss system,
the excitation lines were set at 488 nm and 561 nm. The excitation laser
power under our microscopic settings was determined in accordance with
a previous report (29). The excitation beam was reflected by an MBS
488/561 dichroic mirror and focused by a water immersion objective lens
(C-Apochromat 40/1.2 W Corr M27; Carl Zeiss). The emitted light was
collimated and then split by an NFT 565 dichroic mirror. Emission signals
were detected through a BP 505-540 infrared (IR) emission filter for
mEGFP and a BP 615-680 IR emission filter for HaloTag-TMR. With
respect to the Olympus system, the excitation lines were set at 488 nm and
559 nm. The excitation beam was reflected by a DM 405/488/559 dichroic
mirror and focused by an oil immersion objective lens (60/1.35-numer-
ical-aperture [NA] Uplsapo 60XO; Olympus). The emitted light was
detected through a diffraction grating to measure the fluorescence at
wavelengths of 495 to 540 nm for mEGFP and 575 to 630 nm for HaloTag-
TMR. FCCS measurements were performed for 28 s (Zeiss) and 17 s
(Olympus) for each point and repeated at 7 different points per cell. At
least 10 cells were examined under all conditions. All FCCS experiments
were performed at room temperature.
Spectroscopy by confocal microscopy. HeLa cells were transfected
with a plasmid encoding mEGFP- or HaloTag-fused proteins. Two days after
transfection, the cells were incubated for 15 min with 5 M HaloTag-TMR
ligand at 37°C, washed twice with phosphate-buffered saline (PBS), and in-
cubated for 30 min in DMEM lacking all vitamins (DMEM-V) (30) at 37°C.
Before imaging, cells were washed twice and fed with DMEM-V. Fluorescence
spectra were acquired by using an FV-1000 confocal imaging system (Olym-
pus, Tokyo, Japan). The excitation line was set at 488 nm or 559 nm. The
excitation beam was reflected by a DM 405/488/559 dichroic mirror and
focused by an oil immersion objective lens (Uplsapo 60XO, 1.35 NA; Olym-
pus). Emission signals were detected in the lambda scanning mode.
Calculation of the effective detection volume.The effective detection





where wxy and wz are the lateral and axial 1/e
2 distances, respectively.
These are calculated as
wxy
2  4Dt (5)
wz wxy k (6)
where D and t indicate the diffusion coefficient and the average time for
detected molecules to diffuse out of this volume, respectively, and k is a
structure parameter defined as k wz/wxy. The D value of rhodamine 6G
in water at room temperature was determined previously to be 280m2/s
(31). The t and k values were obtained by fluorescence correlation spec-
troscopy (FCS) measurements with rhodamine 6G in water at room tem-
perature and fitting of the autocorrelation curve using ZEN software (Carl
Zeiss). Thus, wxy and wz were calculated to be 0.24 m and 1.81 m,
respectively, and Veff was determined to be 0.58  0.20 fl under our ex-
perimental conditions.
Data analysis for FCCS. Fluorescent signals were analyzed as described
previously (29, 32). The fluorescence autocorrelation functionGauto(	), from
the mEGFP and HaloTag-TMR channels,GG(	) andGH(	), respectively, and
the fluorescence cross-correlation function,Gcross(	), were calculated accord-
ing to the normalized correlation function:
G()
Ii(t)  Ii(t)Ij(t )  Ij(t)
Ii(t)Ij(t)
(7)
where 	 indicates the time delay; Ii is the fluorescence intensity of the
mEGFP channel (i G) or the HaloTag-TMR channel (iH); the angle
brackets denote the time average; and GG(	), GH(	), and Gcross(	) denote
the autocorrelation functions of mEGFP (i jG), HaloTag-TMR (i
j  H), and the cross-correlation function (i  G or H; j  H or G),








where 	D, k, G(0), and G(
) indicate the correlation time, the structural
parameter, the amplitude of the correlation curve, and the G(	) value
when a correlation functions under steady state, respectively. For fitting,
we used the Excel Solver tool to obtain 	D, G(0), and G(
). The concen-
trations of mEGFP ([EGFPtotal]), HaloTag-TMR ([HaloTagtotal]), and the

























where NA corresponds to the Avogadro number and Veff is the effective
detection volume, determined as described above. The value obtained by
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dividing the cross-correlation amplitude by one of the autocorrelation
amplitudes, called the relative cross-correlation (RCC), provides a direct















where RCCG and RCCH are the relative cross-correlations of EGFP and
HaloTag, respectively. These RCC values were then corrected by the RCC
values obtained from the positive control (RCCPC_G and RCCPC_H), in
which two fluorescent proteins were linked by a short peptide, and the
negative control (RCCNC_G and RCCNC_H), in which two fluorescent pro-
teins were expressed separately and would not bind each other. Thus, the









The values of RCCPC_G, RCCPC_H, RCCNC_G, and RCCNC_H were
measured in every experiment and used to obtain the [cComplex] value.
Calculation of in vivo Kd. According to the definition of Kd, the
fraction of the complex in total EGFP or total HaloTag proteins is derived











Kd EGFPtotal  cComplex
(17)
The fractions of the bound protein in total EGFP and total HaloTag,
i.e., the left-hand terms of equations 16 and 17, were plotted as a function
of free (unbound) HaloTag and EGFP, respectively. The in vivo Kd value
was obtained by nonlinear fitting of the experimental data with equations
16 and 17 and by averaging of these fitted values. For fitting, we used the
Excel Solver function.
Quantification of concentrations of endogenous proteins in HeLa
cells. The protein concentrations of endogenous Shc1, Grb2, MEK1,
MEK2, ERK1, ERK2, RSK1, RSK2, and RSK3 in HeLa cells were deter-
mined as previously described (23). The 5myc-Flag-3HA-tagged (where
HA stands for hemagglutinin) yellow fluorescent protein (YFP) and glu-
tathione S-transferase (GST)-tagged HaloTag were purified from Esche-
richia coli. The lysates of the cells expressing mEGFP-Shc1, Grb2-mEGFP,
MEK1-PAGFP, MEK2-m1YFP, mEGFP-ERK2, HaloTag-RSK1, Ha-
loTag-RSK2, and HaloTag-RSK3 were used as references. The standard
protein (10 ng, 5 ng, and 2.5 ng of 5myc-Flag-3HA-tagged YFP or GST-
tagged HaloTag), the reference protein (a serial dilution of the reference
lysate), and the total cell lysate obtained from 5.0  104, 2.5  104, or
1.25 104 cells were separated by SDS-PAGE, followed by immunoblot-
ting with anti-GFP or anti-HaloTag antibodies (standard and reference)
or specific antibodies (reference and total cell lysate). The bound antibod-
ies were detected and quantified with an Odyssey infrared imaging system
(Li-Cor). The amount of reference protein was determined by the relative
intensity of the reference to 5myc-Flag-3HA-tagged YFP or GST-tagged
HaloTag, and the amount of endogenous protein was calculated from the
intensity of the reference protein. Finally, the concentration of endoge-
nous protein in an individual HeLa cell was determined by dividing the
amount of endogenous protein by the volume of a HeLa cell, which was
3.4 1012 liters (9).
Kinetic modeling and numerical simulation. All kinetic reactions
were described with mass action kinetics with CellDesigner (version 4.1)
(33, 34) (see Fig. 6 and Tables 3 and 4.). Most of the enzymatic reactions
were described as first-order reactions for simplicity. The reactions that
follow the first-order enzymatic kinetics in our model (see Fig. 6) are as
follows: Shc phosphorylation by EGFR (reaction 4), pShc dephosphory-
lation (reaction 5), Ras activation (reactions 11 and 12), Ras inactivation
(reaction 13), Shoc2 activation by EGFR and inactivation (reaction 14),
MEK phosphorylation by Raf (reaction 19), MEK dephosphorylation (re-
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FIG 2 Experimental conditions for in vivo Kd measurement by FCCS. (A) Rela-
tive fluorescence emission spectra of mEGFP and HaloTag-TMR represented as a
function of wavelength. Lines of 488 nm and 559 nm represent the excitation
wavelengths for mEGFP and HaloTag-TMR, respectively. (B and C) HeLa cells
expressing a fusion protein comprised of mEGFP, the GGSGGS linker, and
HaloTag-TMR were subjected to FCCS measurement as a positive control (B). As
a negative control (C), HeLa cells expressing individual mEGFP and HaloTag-
TMR proteins were measured by FCCS. The autocorrelation curves for mEGFP
and HaloTag-TMR and cross-correlation curves for the complex of the positive
control and negative control are plotted as a function of the delay time, 	. Narrow
and bold lines represent raw and fitted correlation curves, respectively. (D) The
relative cross-correlation values for positive controls and negative controls are
regarded as the values in the case of 100% binding and 0% binding, respectively.
These values were measured at every experiment and used as reference values for
correcting the fraction of the complex.
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Among them, MEK dephosphorylation and ERK dephosphorylation were
measured in our previous study (9, 22). The other reactions were approx-
imated as first-order reactions for simplicity. The ordinary differential
equations and parameters were exported to MATLAB software (version
R2008b or R2010b; Mathworks Inc., Natick, MA) through Systems Biol-
ogy Workbench (version 2.7.8) (35). Numerical simulation was per-
formed by using the MATLAB function ode23, a numerical solver of dif-
ferential equations for solving nonstiff problems. The simulation data
calculated by ode23 did not differ from those obtained by ode15s, a nu-
merical solver for stiff differential equations (data not shown). The con-
centrations of each isoform were summed to obtain the total concentra-


















whereAi andBj correspond to the concentration of isoform i (i 1, 2, . . .,
m) of protein A and the concentration of isoform j (j  1, 2, . . ., n) of
protein B, respectively, andKd ij is the dissociation constant of the binding
of Ai and Bj.
RESULTS
Strategy for measuring in vivo Kd. In this study, we attempted to
measure the in vivo Kd between signaling proteins in the EGFR-
Ras-ERK MAP kinase pathway with FCCS and to build a numer-
ical model based on the experimentally verified parameters. Fig-
ure 1C provides a schematic of the procedure for measuring the in
vivo Kd by FCCS. HeLa cells were cotransfected with two plasmids
expressing chimeric proteins A and B, which were fused with dif-
ferent fluorescent proteins. Two or three days after transfection,
we performed FCCS measurements at seven points in the cyto-
plasm of a single HeLa cell and obtained the concentrations of the
fluorescently labeled molecules, [Atotal] and [Btotal], and their
complex, [AB], from y intercepts, G(0), of the auto- and cross-
correlation curves, respectively (Fig. 1C). This analysis was re-
peated with at least 10 cells, and the fractions of [AB] to [Btotal]
were plotted as a function of [Atotal]  [AB]. These plots were
fitted to equations 16 and 17 to obtain the in vivo Kd value. It
should be noted that this measurement requires the assumption of
steady-state conditions, under which the binding reactions are in
equilibrium kinetics.
Optimization of FCCS in HeLa cells. First, we examined
which pairs of fluorescent proteins were most suited for the appli-
cation of FCS/FCCS to living cells. In line with previous studies
using GFP and red fluorescent protein (RFP) as a pair of fluores-
cent proteins for FCCS measurements (12, 36, 37), we tested the
brightness, the degree of bleaching, and triplet formation. As re-
ported previously, mEGFP exhibited sufficiently bright fluores-
cence, a small triplet fraction, and resistance to photobleaching. In
contrast, substantial triplet fractions were detected in tdTomato
and mCherry, as reported previously (38). Furthermore, Foo et al.
reported previously that the low maturation efficiency of mCherry
affected FCCS analysis (38).
To overcome the drawbacks of red fluorescent proteins in
FCCS measurements, we took advantage of HaloTag, which is a
modified haloalkane dehalogenase designed to covalently bind to
synthetic ligands (HaloTag ligands) (39). The complex formed by
conjugation of the HaloTag ligand to the membrane-permeable
HaloTag-tetramethylrhodamine (TMR) ligand, here referred to
FIG 3 Measurement of in vivo Kd values for bindings of signaling molecules in the EGFR-Ras-ERK pathway. The measurements of the in vivo Kd values of the
binding between Shc1-Grb2 (A and B), Grb2-Sos1 (C and D), HRasdCT-G12V–CRaf WT (E), HRasdCT-G12V–BRaf WT (F), MEK2-ERK1 (G), and ERK1-
RSK2 (H) are shown. HeLa cells were transfected with plasmids expressing the indicated fusion proteins. Two or three days after transfection, the cells were
treated with the TMR ligand, followed by serum starvation. The cells were then subjected to FCCS measurements. The fraction of the complex compared to the
total HaloTag-TMR-fused proteins was plotted as a function of unbound mEGFP-fused proteins. EGF with Na3VO4 (B and D) was treated 30 min before FCCS
measurements were started.
Sadaie et al.
3276 mcb.asm.org Molecular and Cellular Biology
 o
n










as HaloTag-TMR, did not show detectable photobleaching or a
detectable triplet fraction under these imaging conditions, indi-
cating that this complex would have practical advantages for
FCCS measurements. We acquired the fluorescence spectra of
mEGFP and HaloTag-TMR in HeLa cells (Fig. 2A) and selected
completely separable emission filters for mEGFP (505 to 540 nm)
and HaloTag-TMR (615 to 680 nm).
We next performed FCCS by using a positive control and a
negative control (Fig. 2B and C). A chimeric protein consisting of
mEGFP, the GGSGGS linker, and HaloTag-TMR was used as a
TABLE 1 Comparison of in vivo Kd values obtained in this study with in vitro Kd values measured previously by in vitro experiments
a
Binding
This study Previous studies
In vivo




Mean in vitro Kd
(M) SD Methodc Reference
Grb2-pShc 0.23 55 SPR 61
1.4d 0.7, 2.1 30 0.031 8 SPR 61
0.023 SPR 41
Grb2-Sos1 1.7 1.2, 2.2 23 0.001 Co-IP 62
6.5d 3.3, 9.7 21 0.4 ITC 63
2.8e 1.7, 3.9 18 21.4 5.9 ITC 64
2.1f 1.2, 1.5 16 1.7 0.1 SPR 64
p110-p85 0.1 24 NR
HRas-CRafg 6.9 4.2, 9.6 34 0.12 ITC 65
2.3h 1.7, 2.9 27 0.13 GDI assay 66
0.0021 SPR 67
HRas-BRaff 3.1 2.5, 3.7 33 0.0011 SPR 67
3.5i 2.7, 4.3 28
MEK1-ERK1 6.6 3.1, 10.1 22 0.058 Stopped flow 68
MEK1-ERK2 0.046–0.476 Michaelis constant 69
11 7.2, 15 24 0.34 0.06 Michaelis constant 70
1.5 SPR 9
MEK2-ERK1 8.1 5.8, 10 24 NR
MEK2-ERK2 5.6 3.8, 7.3 26 NR
ERK1-RSK1 1.7 0.85, 2.5 22 NR
ERK2-RSK1 0.87 0.54, 1.2 25 0.15 0.01 SPR 71
ERK1-RSK2 2.1 1.5, 2.8 36 NR
ERK2-RSK2 1.3 0.93, 1.7 36 NR
ERK1-RSK3 1.0 0.51, 1.4 23 NR
ERK2-RSK3 0.7 0.47, 0.91 27 NR
MEK1-KSR1 1.5 0.99, 2.0 25 NR
MEK1-KSR2 1.2 0.79, 1.6 23 NR
MEK2-KSR1 1.3 0.77, 1.9 35 NR
MEK2-KSR2 1.1 0.54, 1.6 22 NR
a The in vivo Kd values quantified by FCCS in this study were compared with in vitro Kd values that were previously determined by in vitro experiments. NR, not reported.
b CI, confidence interval.
c SPR, surface plasmon resonance; co-IP, coimmunoprecipitation; ITC, isothermal calorimetry; GDI, guanine nucleotide dissociation inhibitor.
d In the presence of 10 ng/ml EGF and Na3VO4.
e In the presence of 1 mM TPA.
f In the presence of 10 M PD-184352 (MEK inhibitor), 10 ng/ml EGF, and 10 mM Na3VO4.
g Carboxyl-terminus-deleted cytoplasmic HRas-G12V mutant.
h CRaf-S259A mutant.
i BRaf-S364A mutant.
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positive control. mEGFP and HaloTag expressed separately in
cells were used as a negative control. We measured the autocorre-
lation functions of mEGFP (Fig. 2B and C, green lines) and
HaloTag-TMR (red lines) and the cross-correlation function
(blue lines). Ideally, with the positive-control sample, the y inter-
cept of the autocorrelation function of GFP, GG(0), must be iden-
tical to that of HaloTag-TMR, GH(0), and also identical to the y
intercept of the cross-correlation function, Gcross(0). In the case of
the negative-control sample,Gcross(0) must be equal to 0. Thus, the
relative cross-correlation (RCC) values, which represented the
FIG 4 Computer simulation of the effects of endogenous competitors on measurements of in vivo Kd values. (A) Schematic competitive binding model. Green
fluorescent protein-fused exogenous protein A binds to red fluorescent protein-fused exogenous protein B. Endogenous proteins C and D competitively bind to
proteins A and B, respectively. Dissociation constants for all bindings in this model were assumed to be 0.1 M. The species measured by the autocorrelation
function (ACF) and cross-correlation function (CCF) are indicated in the insets. (B) Comparison among three fitting methods for in vivo Kd calculations. While
fitting methods 1 and 2 were applied in this study, Foo et al. (38) previously employed fitting method 3. (C to E) The initial concentrations of proteins A and B
were set randomly with a fixed concentration set of competitor proteins C and D. The concentrations of the AB protein complex, [AB], at steady state were
calculated in accordance with the competitive binding model shown in panel A. Simulated results were plotted and fitted according to fitting method 1 (C), fitting
method 2 (D), and fitting method 3 (E). Even though the concentrations of endogenous competitor proteins C and D were fixed values, the simulated plots varied
widely from the fitting curves. (F and G) Heat maps showing the logarithmic in vivo Kd values obtained by averaging fitting methods 1 and 2 (F) and by fitting
method 3 (Kd3) (G), with the indicated concentration set of competitor proteins C and D. (H and I) Heat maps showing the coefficient of determination (R
2)
values obtained by averaging fitting methods 1 and 2 (H) and by fitting method 3 (I) with the indicated concentration sets of competitor proteins C and D. In
several concentration sets of competitor proteins C and D, fitting methods 1 and 2 showed higher values for the coefficient of determination than those obtained
by fitting method 3, indicating the advantage of the former method.
Sadaie et al.
3278 mcb.asm.org Molecular and Cellular Biology
 o
n










fraction of the complex, theoretically must be 1 and 0 for the
positive and negative controls, respectively. In our FCCS setup,
the RCC values were within the range of 0.7 to 1.0 and 0.02 to 0.15
for the positive and negative controls, respectively (Fig. 2D). This
deviation could be attributed to the imperfect overlap of the effec-
tive volumes of the two excitation lasers (38) and the spectral
bleedthrough of EGFP fluorescence into the HaloTag-TMR emis-
sion channel. Therefore, we corrected the fraction of bound pro-
tein by using the RCC values of the positive and negative controls
as 100% binding and 0% binding on each day of imaging, respec-
tively (for more details, see Materials and Methods).
Measurement of in vivo Kd values of protein complexes in
the EGFR-Ras-ERK MAP kinase pathway. By using the method
described above, we quantified the in vivo Kd values of protein
complexes that transmit signals in the EGFR-Ras-ERK MAP ki-
nase pathway in living HeLa cells (Fig. 3 and see Table 2).
The adaptor protein Grb2 binds to another adaptor protein,
Shc1, in a phosphotyrosine-dependent manner (40). In agree-
ment with this property, the in vivo Kd value of the Grb2-Shc1
complex was 15 M without growth factor stimulation (Fig.
3A). To maximize the tyrosine phosphorylation of Shc1, HeLa
cells were stimulated with EGF in the presence of Na3VO4, a ty-
rosine phosphatase inhibitor. Under these conditions, the Kd
value of the Grb2-Shc1 complex was 1.4M (Fig. 3B and Table 1).
The in vivo Kd value was slightly higher than or comparable to
those obtained in vitro (40, 41). Next, the Kd value of the Grb2-
Sos1 complex mediated by the SH3 domain was determined to be
approximately 1.7M (Fig. 3C and Table 1). TheKd was increased
to 6.5M in EGF- and Na3VO3-treated cells (Fig. 3D and Table 1).
This increase in the Kd was cancelled by the MEK inhibitor (Table
1). These data were consistent with the negative-feedback mech-
anism showing that Sos1 phosphorylation by ERK reduced the
affinity of binding between Sos1 and Grb2 (42–44).
HRas localizes at the plasma membrane and Golgi apparatus
via the lipid-modified C terminus (45, 46). We attempted to mea-
sure the binding between HRas-G12V, which was a constitutively
active mutant, and CRaf. However, because of the slow diffusion
of HRas at the plasma membrane, we failed to measure the in vivo
Kd value for the binding of HRas-G12V to CRaf. To overcome this
problem, we deleted the carboxyl terminus of HRas and prepared
the cytoplasmic HRasdCT-G12V mutant (24). TheKd value of the
HRasdCT-G12V–CRaf complex was 6.9 M (Fig. 3E). Interest-
ingly, the CRaf-S259A mutant, which adopts an open active con-
formation (24), bound to HRasdCT-G12V more strongly than did
the CRaf wild type (WT), with an in vivoKd of 2.3M (Table 1). In
contrast, an equivalent mutation in BRaf, S364A, did not decrease
the Kd value of the complex formed by HRasdCT-G12V and BRaf
(Fig. 3F and Table 1), suggesting that the phosphorylation of BRaf
at S364 plays a different role in Ras binding than the phosphory-
lation of CRaf at S259.
MEK has been shown to bind to and sequester ERK in the
cytoplasm (47). ERK also binds to RSK through the D domain of
the RSK LXL (DEJL) motif (48–50). There were also isoforms of
them, MEK1, MEK2, ERK1, ERK2, RSK1, RSK2, and RSK3. We
measured 10 possible combinations of the bindings among them
(Fig. 3G and H and Table 1). We did not find any remarkable
difference among the isoforms; therefore, the isoforms of MEK,
ERK, and RSK were handled as single proteins in the simulation
model described below.



















































FIG 5 Quantitative map of the EGFR-Ras-ERK signaling pathway in a HeLa
cell. (A) Protein concentrations of endogenous MEK1 in a HeLa cell were
determined by quantitative Western blotting, as described in Materials and
Methods. (B) Schematic representation of the in vivo Kd map of the EGFR-
Ras-ERK pathway. The diameter of the circles represents the concentration of
the indicated protein, and the line thickness indicates the in vivo Kd values in a
HeLa cell.
TABLE 2 Concentrations of signaling molecules in the EGFR-Ras-ERK
pathway in a HeLa cella
Protein No. of molecules/cell Concn (M) Reference
EGFR 0.42 22
p46 Shc 1.4 105 0.068 This study
p52 Shc 1.7 105 0.083 This study
Grb2 2.9 105 0.14 This study
Sos1 0.12 22
Ras 0.43 51
BRaf 7.5 104 0.037 This study
CRaf 0.013 51
MEK1 2.6 105 0.13 This study
MEK2 1.5 106 0.74 This study
ERK1 2.4 105 0.12 This study
ERK2 1.4 106 0.68 This study
RSK1 1.5 105 0.073 This study
RSK2 3.1 105 0.15 This study
RSK3 1.1 105 0.054 This study
a Protein concentrations in a single HeLa cell were determined by dividing the number
of molecules by a cell volume of 3.4 pl in a HeLa cell (9).
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regulatory subunit and a p110 catalytic subunit. The Kd value of
the PI3-K complex was 0.1 M (Table 1). We could not pre-
cisely determine the Kd value by nonlinear curve fitting, because
the lower detection limit of the concentration for mEGFP and
HaloTag-TMR was ca. 0.1 M under our experimental condi-
tions.
Evaluation of the effects of competitive bindings on in vivo
Kd values by computer simulation. Most of the in vivo Kd values
obtained in this study were higher than the in vitro Kd values
reported previously by an order of 1 or 2 (Table 1). This discrep-
ancy strongly suggested that competitive binding had a greater
effect on the in vivo Kd values than did molecular crowding. It
should be noted that the large variability of each experimental plot
from the fitting curve was caused by competitive binding. We
simulated the effect of a fixed concentration of endogenous com-
petitors on the in vivo Kd calculation by randomly changing the
concentrations of two fluorescently labeled molecules (Fig. 4A
and B). As expected, the in vivo Kd value was increased with the
increase in the concentrations of endogenous competitors (Fig.
4C to E). The simulated plots were largely varied and dispersed,
even though the concentrations of competitor proteins were fixed
at constant values, as shown by the experimental data (Fig. 3).
These simulation data were basically consistent with data reported
in a previous study by Foo et al. (38). We compared fitting meth-
EGFR-Shc-Grb2-Sos module
Ras-Raf activation module
ERK-Sos negative feedback module
























The reaction in which parameter(s) were measured in this study.
The reaction in which parameter(s) were measured in other studies.
The reaction in which parameter(s) were estimated based on experimental data.






































































































































FIG 6 Kinetic simulation model of the EGFR-Ras-ERK MAP kinase pathway. The schematic of the EGFR-Ras-ERK pathway, which was created with Cell-
Designer (33), includes four modules: the EGFR-Shc-Grb2-Sos module (1), the Ras-Raf activation module (2), the MEK-ERK processive phosphorylation
module (3), and the ERK-Sos negative-feedback module (4). The reaction identification (Re) number is indicated for each reaction. For more details, see Tables
3 and 4.
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ods 1 and 2, which were used in this study, with fitting method 3,
which was used in the study by Foo et al., and found that all of
these methods provided almost the same in vivo Kd values (Fig. 4F
and G). However, fitting methods 1 and 2 showed higher values
for the coefficient of determination (R2) between the fitting and
simulation data than fitting method 3 (Fig. 4H and I). Therefore,
we applied these fitting methods to the measurement of in vivo Kd
values in this study.
Quantitative in vivo Kd map of the EGFR-Ras-ERK MAP
kinase pathway. Quantitative Western blot analyses were used to
measure the endogenous concentrations of proteins comprising
the EGFR-Ras-ERK MAP kinase pathway in individual HeLa cells,
including Shc, Grb2, MEK1, MEK2, ERK1, ERK2, RSK1, RSK2,
and RSK3 (Fig. 5A and Table 2). These results, taken together with
our previous data (22, 25, 51), are summarized in Table 2. Taking
the in vivo Kd data (Table 1) and endogenous protein concentra-
tions in a HeLa cell (Table 2) into account, we drew a quantitative
interaction map of the EGFR-Ras-ERK MAP kinase pathway (Fig.
5B). In this scheme, the in vivo Kd values of Ras-CRaf and Ras-
BRaf were the same as those of constitutively active Ras. There-
fore, with the low abundance of Raf proteins, we speculated that
signaling from Ras to Raf is the most inefficient part of the signal
transduction pathway.
Model of the EGFR-Ras-ERKMAP kinase pathway. We built
a simulation model of the EGFR-Ras-ERK MAP kinase pathway
(Fig. 6 and Tables 3 and 4). This model was comprised of 4 mod-
ules, the EGFR-Shc-Grb2-Sos module, the Ras-Raf activation
module (52), the MEK-ERK processive phosphorylation module
(9), and the ERK-Sos1 negative-feedback module (22). EGFR was
phosphorylated (pEGFR) upon EGF stimulation. Shc was phos-
phorylated by pEGFR, followed by binding to Grb2 and/or the
Grb2-Sos complex. The pShc-Grb2-Sos ternary complex was as-
sociated with pEGFR. The bindings of Grb2 or the Grb2-Sos com-
plex to pEGFR were ignored because we could not observe Grb2
binding to pEGFR in HeLa cells and A431 cells upon EGF stimu-
lation (our unpublished observations), and we did not include the
bindings of Shc, pShc, or pShc-Grb2 to pEGFR to avoid unneces-
sary complexity of the model.
The in vivo Kd values obtained in this study were used as the
kinetic parameters to define 14 reactions in the model (Fig. 6,
magenta lines), in addition to Shc phosphorylation/dephosphor-
ylation rates (reactions 4 and 5) (Fig. 6 and 7A and B), the time
course of EGFR and MEK phosphorylation upon EGF stimulation
(Fig. 7C to E), and RSK1/RSK2/RSK3 nuclear import/export rates
(reaction 36) (Fig. 6 and 7F and G). To constrain the parameters
during simulation, we measured the stoichiometry of MEK phos-
phorylation by Phos-tag Western blotting (53) (Fig. 7H to K).
Roughly 33% of MEK1/2 proteins were phosphorylated at Ser217/
221 residues by Raf 10 min after EGF stimulation. Other kinetic
parameters were either determined experimentally (Fig. 6, green
lines) or estimated from experimental data from previous studies
(22, 51) (Fig. 6, cyan lines).
Numerical simulation of the EGFR-Ras-ERK MAP kinase
pathway based on in vivo Kd values. Numerical simulation of
EGF-induced changes in the activity of EGFR (pEGFR), Ras (Ras-
GTP), MEK (pMEK), and ERK (pTpY-ERK) in this original
model demonstrated much lower values for Ras, MEK, and ERK
than those obtained in experiments (Fig. 8A). This could be rea-
sonable because in vivo Kd values obtained in this study were sub-
stantially higher than those used in the original models. We exam-
ined which reactions were rate-limiting steps and found three
responsible reactions: from upstream, association of the pShc-
Grb2-Sos complex with pEGFR (Fig. 8B, left), MEK phosphory-
lation by Raf (Fig. 8B, middle), and ERK phosphorylation by MEK
(Fig. 8B, right). The latter two reactions were updated with the in
vivo Kd values obtained in this study, resulting in decreases of the
affinity of Ras-Raf binding and MEK-ERK binding, respectively.
These reductions were corrected by multiplying the constant val-
ues, which approximately corresponded to the fold change in the
reduction. Meanwhile, the detailed mechanisms of the association
of the pShc-Grb2-Sos complex with pEGFR were not addressed,
because we could not measure the dissociation constant of the
reaction that took place at the plasma membrane.
Role of multiple Shc bindings to pEGFR. To assess the role of
pEGFR-Shc binding, we examined the dissociation constant and
stoichiometry of binding by employing our quantitative simula-
tion model. The phosphotyrosine binding (PTB) domain of Shc1
has been reported to interact with multiple sites of phosphory-
lated tyrosine residues of pEGFR. Jones et al. previously measured
the dissociation constants of bindings between the Shc1 PTB do-
main and 6 phosphotyrosine residues of pEGFR by using protein
microarrays. The in vitro Kd values were 0.040 M for pY1172,
0.133 M for pY1138, 0.317 M for pY1192, 0.321 M for
pY1110, 0.628 M for pY1016, and 1.152 M for pY998 (54). To
examine the role of these multiple binding sites, we numerically
changed the parameters of binding between pEGFR and Shc, with
ranges of 0.001M to 10M for the dissociation constant and 0 to
6 for stoichiometry, and calculated the residual sum square (RSS)
values, which were a measure of how well the simulated data set fit
with the experimental data. In Fig. 8C, blue represents a better fit
to the experimental data. If a single binding site, namely, a stoi-
chiometry value of 1, was assumed in the model, the best fit was
obtained with aKd value of 0.057M, which seemed to be implau-
sible because this value was almost comparable to the lowest in
vitro Kd value of pEGFR-Shc binding, 0.040 M (54). Further-
more, the time courses of activation of Ras, MEK, and ERK were
very dull under this condition (Fig. 8D). On the other hand, both
the dissociation constant and stoichiometry were fitted to the ex-
perimental data, providing values of 0.250 M and 5.9, respec-
tively (Fig. 8C and E). We set the Kd value at 0.25 M and exam-
ined the effect of stoichiometry on the time courses of activation
TABLE 3 Initial concentrations of signaling molecules in simulationsa
Protein Concn (M) Description or reference
EGF 0.016 10 ng/ml
EGFR 0.42 22
Shoc2 0.67 72
Shc 0.15 This study
Grb2 0.14 This study
Sos1 0.12 22
Ras 0.43 51
BRaf 0.037 This study
CRaf 0.013 51
MEK 0.87 This study
ERK 0.79 This study
RSK 0.28 This study
RasGEF 1.0 22
RasGAP 1.0 22
a The initial concentrations of species in the simulation model are listed. The
concentrations of isoforms, e.g., MEK1 and MEK2, are summed simply.
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TABLE 4 Kinetic reactions and parametersf
Reaction






1 EGF EGFRN pEGFR kf 100 M/s Estimated from Fig. 7
kf · EGF · EGFR kb · pEGFR kb 0.15 s Estimated from Fig. 7
2 EGF_EGFR¡ pEGFR_degra kf 0.002 s Estimated from Fig. 7
kf · pEGFR
3 pEGFR_degra¡ EGFR kf 0.001 s Estimated from Fig. 7
kf · pEGFR_degra
4 Shc pEGFR¡ pShc kf 0.031 M/s Quantified in Fig. 7
a
kf · pEGFR · Shc
5 pShc¡ Shc kf 0.028 s Quantified in Fig. 7
a
kf · pShc
6 pShc Grb2N pShc_Grb2 kf 0.1 M/s Calculated from in vivo
Kd value
b
kf · pShc · Grb2 kb · pShc_Grb2 kb 0.14 s
7 Grb2 Sos1N Grb2_Sos1 kf 0.1 M/s Calculated from in vivo
Kd value
b
kf · Grb2 · Sos1 kb · Grb2_Sos1 kb 0.17 s
8 pShc_Grb2 Sos1N pShc_Grb2_Sos1 kf 0.1 M/s Calculated from in vivo
Kd value
b
kf · pShc_Grb2 · Sos1 kb · pShc_Grb2_Sos1 kb 0.17 s
9 pShc Grb2_Sos1N pShc_Grb2_Sos1 kf 0.1 M/s Calculated from in vivo
Kd value
b
kf · pShc · Grb2_Sos1 kb · pShc_Grb2_Sos1 kb 0.14 s
10 pEGFR n · pShc_Grb2_Sos1N pEGFR_(pShc_Grb2_Sos1)n kf 0.1 M/s See text






[pShc_Grb2_Sos1) n · (kf · pEGFR · pShc_Grb2_Sos1 kb ·
pEGFR_(pShc_Grb2_Sos1)n]
n (1c,d, 5.9e)
11 RasGDP pEGFR_(pShc_Grb2_Sos1)n (enzyme)¡ RasGTP kf 1 M/s 73
kf · n · pEGFR_(pShc_Grb2_Sos1)
n · RasGDP n (1c,d, 5.9e) See text
12 RasGDP RasGEF¡ RasGTP kf 0.00005 M/s 22
kf · RasGEF · RasGDP
13 RasGTP RasGAP¡ RasGDP kf 0.05 M/s 22
kf · RasGAP · RasGTP
14 Inactive_Shoc2 pEGFR (enzyme)N Active_Shoc2 kf 0.1 M/s 52
kf · inactive_Shoc2 · pEGFR kb · active_Shoc2 kb 0.1 s
15 RasGTP cRafN Ras_cRaf kf 0.1 M/s Calculated from in vivo
Kd value
b
kf · RasGTP · cRaf kb · Ras_cRaf kb 0.23 s
16 RasGTP BRafN Ras_BRaf kf 0.1 M/s Calculated from in vivo
Kd value
b
kf · RasGTP · BRaf kb · Ras_BRaf kb 0.31 s
17 RasGTP active_Shoc2N Ras_Shoc2 kf 1 M/s 52
kf · RasGTP · active_Shoc2 kb · Ras_Shoc2 kb 0.1 s
(Continued on following page)
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18 Ras_Shoc2 cRafN Ras_Shoc2_cRaf kf 0.1 M/s Calculated from in vivo
Kd value
b
kf · Ras_Shoc2 · cRaf kb · Ras_Shoc2_cRaf kb 0.23 s
19 MEK_cyt (Ras_cRaf Ras_BRaf Ras_Shoc2_cRaf)
¡ pMEK_cyt
kf (1
c, 10d,e) M/s See text
kf · MEK_cyt · (Ras_cRaf Ras_BRaf Ras_Shoc2_cRaf)
20 pMEK_cyt¡MEK_cyt kf 0.0096 s 9
kf · pMEK_cyt
21 MEK_cyt ERK_cytNMEK_ERK_cyt kf 0.1 M/s Calculated from in vivo
Kd value
b
kf · MEK_cyt · ERK_cyt kb · MEK_ERK_cyt kb 0.66 s
22 ERK_cyt RSK_cytN ERK_RSK_cyt kf 0.1 M/s Calculated from in vivo
Kd value
b
kf · ERK_cyt · RSK_cyt kb · ERK_RSK_cyt kb 0.12 s
23 pMEK_cyt ERK_cytN pMEK_ERK_cyt kf 0.1 M/s Calculated from in vivo
Kd value
b
kf · pMEK_cyt · ERK_cyt kb · pMEK_ERK_cyt kb 0.66 s





25 pMEK_pYERK_cyt¡ pTpYERK_cyt pMEK_cyt kf 0.05 M/s 9
kf · pMEK_pYERK_cyt
26 pTpYERK_cyt¡ pYERK_cyt kf 0.004 M/s 9
kf · pTpYERK_cyt
27 pTpYERK_cyt¡ pTERK_cyt kf 0.0055 M/s 9
kf · pTpYERK_cyt
28 pYERK_cyt¡ ERK_cyt kf 0.0067 M/s 9
kf · pYERK_cyt
29 pTERK_cyt¡ ERK_cyt kf 0.0068 M/s 9
kf · pTERK_cyt
30 pYERK_cyt pMEK_cyt¡ pTpYERK_cyt kf 0.021 M/s 9
kf · pYERK_cyt · pMEK_cyt
31 pTERK_cyt pMEK_cyt¡ pTpYERK_cyt kf 0.02 M/s 9
kf · pYERK_cyt · pMEK_cyt
32 ERK_cytN ERK_nuc kf 0.0017 s 9
kf · ERK_cyt kb · ERK_nuc kb 0.013 s
33 pYERK_cytN pYERK_nuc kf 0.0025 s 9
kf · pYERK_cyt kb · pYERK_nuc kb 0.017 s
34 pTERK_cytN pTERK_nuc kf 0.0022 s 9
kf · pTERK_cyt kb · pTERK_nuc kb 0.049 s
35 pTpYERK_cytN pTpYERK_nuc kf 0.0082 s 9
kf · pTpYERK_cyt kb · pTpYERK_nuc kb 0.0076 s
(Continued on following page)
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of Ras, MEK, and ERK. We found that high stoichiometry is es-
sential to recapitulate the peak activations of Ras, MEK, and ERK
(Fig. 8E).
The prediction by the simulation model urged us to confirm
experimentally the stoichiometry of Shc binding to EGFR. For
this, we first established two stable HeLa cell lines expressing
mEGFP or HaloTag, which were used to calibrate the concentra-
tions of mEGFP and HaloTag by FCS. Next, HeLa cells stably
expressing both EGFR-mEGFP and HaloTag-Shc were stimulated
with EGF for 15 min to induce accumulation of EGFR-mEGFP
and HaloTag-Shc on the endosomes (Fig. 8F and G). The concen-
tration ratio of EGFR-mEGFP to HaloTag-Shc was determined on
each endosome and plotted in a histogram (Fig. 8H). We found
that approximately 3 Shc molecules associated with EGFR at en-
dosomes upon EGF stimulation.
DISCUSSION
In this study, we established a method for obtaining the in vivo Kd
in living cells by FCCS and used this method to determine 22 in
vivo Kd values for the EGFR-Ras-ERK MAP kinase pathway. By
combining these in vivo Kd values with intracellular concentra-
tions quantified by Western blotting, we built a simulation model
of this signaling pathway. This model indicated the possible effect
of multivalent binding of Shc proteins to pEGFR on sufficient
peak activations of Ras, MEK, and ERK. Therefore, to the best of
our knowledge, this study is the first to show the essential role
played by multiple Shc bindings to pEGFR in the EGFR signaling
pathway. These results clearly demonstrate the validity of this
method and quantitative simulation model. However, there are
substantial discrepancies between the experimental and simulated
results, especially for the transient peak activity and sustained
TABLE 4 (Continued)
Reaction






36 RSK_cytN RSK_nuc kf 0.001 s Quantified in Fig. 7F
and G
kf · RSK_cyt kb · RSK_nuc kb 0.11 s Data not shown
37 ERK_nuc RSK_nucN ERK_RSK_nuc kf 0.1 M/s Calculated from in vivo
Kd value
b
kf · ERK_nuc · RSK_nuc kb · ERK_RSK_nuc kb 0.12 s
38 pTpYERK_nuc¡ pYERK_nuc kf 0.0032 s 9
kf · pTpYERK_nuc
39 pTpYERK_nuc¡ pTERK_nuc kf 0.0038 s 9
kf · pTpYERK_nuc
40 pYERK_ nuc¡ ERK_nuc kf 0.0077 s 9
kf · pYERK_nuc
41 pTERK_ nuc¡ ERK_nuc kf 0.0058 s 9
kf · pTERK_nuc
42 Sos1 pTpYERK_cytN pSos1 kcat 0.02 M/s 22
kcat · pTpYERK_cyt · Sos1/(Km Sos1) kb · pSos1 Km 1 M
kb 0.0025 s
43 pSos1 pTpYERK_cytN ppSos1 kcat 0.02 M/s 22
kcat · pTpYERK_cyt · pSos1/(Km pSos1) kb · ppSos1 Km 1 M
kb 0.0025 s
44 ppSos1 pTpYERK_cytN pppSos1 kcat 0.02 M/s 22
kcat · pTpYERK_cyt · ppSos1/(Km ppSos1) kb · pppSos1 Km 1 M
kb 0.0025 s
45 pppSos1 pTpYERK_cytN ppppSos1 kcat 0.02 M/s 22




a The enzymatic reaction was treated as a first-order enzymatic reaction.
b The kf value was set to 0.1 mM/s. The kb value was calculated from the kf and in vivo Kd values obtained in this study (Table 1).
c The value is used in Fig. 8A.
d The value is used in Fig. 8D.
e The value is used in Fig. 8E.
f Reaction identification numbers correspond to the numbers in Fig. 6. Boldface type denotes enzymes.
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basal activity of MEK and ERK upon EGF stimulation (Fig. 8E),
suggesting the existence of other possible regulations to be ad-
dressed in the future.
The in vivo Kd is influenced by both competitive binding by a
number of proteins and molecular crowding (Fig. 1B). Competi-
tive bindings increase the in vivo Kd value, whereas molecular
crowding decreases the in vivo Kd value through the excluded-
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FIG 7 Quantifications of kinetic parameters for EGFR-Ras-ERK signaling. (A and B) Shc1 phosphorylation and dephosphorylation rates (reactions 4 and 5) (Fig. 6).
Serum-starved HeLa cells were treated with 50 ng/ml EGF, followed by the addition of an EGFR inhibitor, 10M PD-153035, 5 min later. Cell lysates were subjected to
Western blotting with antiphosphotyrosine and anti-pY317-Shc antibodies. Representative results of three independent experiments are shown (A). Averaged pShc
intensity values were plotted as a function of time, with standard deviations (B). First, the pShc dephosphorylation rate constant was measured by fitting the experimental
data with a single exponential function (blue line). The time constant of the fitted exponential function corresponds to the pShc dephosphorylation rate constant. Second,
the Shc phosphorylation rate constant was calculated as follows. The time constant of phosphorylation was obtained by fitting the experimental data with a single
exponential function (red line). The time constant value was subtracted from the pShc dephosphorylation rate constant and then divided by the EGFR concentration,
providing the Shc phosphorylation rate by pEGFR. AU, arbitrary units. (C to E) Time courses of EGF-induced phosphorylation of EGFR and MEK1/2 in HeLa cells were
examined by Western blotting (C) and quantified by densitometry (D and E). (F and G) Nuclear import and export rates of RSK1, RSK2, and RSK3 proteins. HeLa cells
expressing HaloTag-fused RSK1, RSK2, or RSK3 were treated with the TMR ligand, followed by confocal microscopy (F), and the ratio of fluorescence intensity in the
nucleus to that in the cytoplasm was quantified (G). The concentration ratio is equal to the ratio of the nuclear import rate to the nuclear export rate. Therefore, we set
the nuclear import rate at 0.001/s, and the nuclear export rates were calculated by the ratio of nuclear intensity to cytoplasmic intensity. Bar, 15 m. (H to K)
Stoichiometry of phosphorylated MEK. Recombinant GST-MEK1 protein was phosphorylated invitroby constitutively active CRaf kinase for the indicated time periods.
The eluates were subjected to Phos-tag Western blotting. The fraction of phospho-GST-MEK1 was measured by the reduction of nonphosphorylated GST-MEK1 (H,
left). The same eluates were also subjected to conventional Western blotting (I). The fractions of phosphorylated MEK1 were plotted as a function of the pMEK/MEK
ratio and fitted with a linear function (K). EGF-stimulated HeLa cell lysates were analyzed by conventional Western blotting (J), and the fraction of phosphorylated
MEK1/2 was calculated by using the reference function obtained in panel K.
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vivo Kd values determined in this study were higher than those
measured previously in in vitro assays (Table 1). These findings
suggested that competitive bindings, rather than molecular
crowding, made a more significant contribution to in vivo Kd val-
ues. Of note, we could not exclude other potential explanations for
the increased in vivo Kd values, such as changes in conformation
and molecular crowding, under certain circumstances. Foo et al.
reported previously that the in vivo Kd values of Cdc42 and its
effectors could become close to the in vitro Kd values by introduc-
ing correcting factors, such as the maturation efficiency of fluo-
rescent proteins, photobleaching, and fluorescence resonance en-
ergy transfer (FRET) (38). The application of these corrections to
our data might lead to an improvement in the discrepancies be-
tween the in vivo and in vitro Kd values to some extent. However,
the increase in in vivo Kd values is unavoidable and remarkable in
the binding of a protein containing multiple domains for protein-
protein bindings, such as adaptor molecules. Although we could
not entirely exclude the possibility that other factors such as ionic
strength alter Kd values, in vivo Kd values have a potential advan-
tage to directly demonstrate how much proteins form complexes
in living cells.
The quantitative in vivo Kd measurements clarified several reg-
ulatory mechanisms underlying the EGFR-Ras-ERK pathway. Re-
search groups have studied the role of growth factor-induced Sos1
phosphorylation but have not reached the same conclusion. Sos1
has at least 4 serine residues phosphorylated mainly by ERK in the
C-terminal domain, resulting in negative regulation of Sos1 as a
Ras activator. Two regulatory mechanisms have been suggested
for the phosphorylation-mediated negative regulation of Sos1: a
phosphorylation-induced disassembly of the Grb2-Sos1 complex
(42, 43) and a phosphorylation-induced dissociation of the Grb2-
Sos1 complex from the activated EGF receptors (40, 55). How-
ever, most of those experiments were performed under in vitro
conditions. Our results revealed that pretreatment with TPA or
EGF and Na3VO4 increased the in vivo Kd value of the Grb2-Sos1
complex (Fig. 3C and D and Table 1), supporting the former
mechanisms for negative feedback from ERK to Sos1. In addition,
we found that HRasdCT-V12 bound preferentially to the CRaf-
S259A mutant rather than to the CRaf WT (Fig. 3E and Table 1).
This result agreed with previously reported findings showing a
sequential state transition model of CRaf for its Ras binding; CRaf
phosphorylated on Ser259 adopts a closed inactive conformation,
and dephosphorylation of Ser259 induces CRaf to adopt a semi-
closed inactive state to associate with Ras-GTP (24). In contrast,
the in vivo Kd values for HRas binding to the BRaf WT and the
BRaf-S364A mutant, which corresponded to the CRaf-S259A mu-
tant, did not show any difference (Table 1). These results indicated
a clear difference between Ras-CRaf WT binding and Ras–CRaf-
S259A binding but not between Ras-BRaf WT and Ras–BRaf-
S364A binding (Fig. 3 and Table 1). It has been well characterized
that 14-3-3 binds to the CRaf S259 phosphorylation site to form a
closed inactive state (24), and the BRaf S364 phosphorylation site
is thought to be equivalent to the CRaf S259 phosphorylation site.
We suggest that the CRaf S259 site is highly phosphorylated even
in the basal state, and therefore, most CRaf WT proteins form a
closed state, while the BRaf S364 site is not sufficiently phosphor-
ylated, and therefore, a substantial amount of BRaf WT proteins
form an open state. The other possibility is that another phospho-
serine residue serves as the 14-3-3 binding site in BRaf (25). No-
tably, for technical reasons, we had to omit some important reg-
ulatory mechanisms. For example, in vitro analyses of CRaf-lipid
interactions have revealed two distinct phospholipid binding re-
gions within CRaf, at amino acid residues 139 to 184 and 390 to
423, for phosphatidylserine and phosphatidic acid, respectively
(56, 57). These two regions function to promote translocation of
CRaf to the membrane and to increase the affinity for GTP-Ras.
Therefore, we might have overestimated in vivo Kd values of Ras-
Raf binding, which was measured only in the cytoplasm. Even
with this kind of limitation, we believe that measurements of in
vivo Kd values by FCCS will provide compelling quantitative data
for interactions in living cells.
We improved and optimized some of the experimental condi-
tions of FCCS for our in vivo Kd measurements. EGFP and
mCherry have hitherto been utilized as a fluorescent protein pair
for FCCS measurements (12, 36, 37). However, the mCherry pro-
tein has been reported to exhibit slower chromophore matura-
tion, a much greater triplet component, weaker photostability
than the EGFP protein, and, consequently, a decrease in the sig-
nal-to-noise ratio of FCCS measurements (38). We found that
HaloTag-TMR overcame all these flaws. The membrane-perme-
able TMR ligand needs to be added after HaloTag expression in
cells. Based on the positive-control data, almost all HaloTag pro-
teins were covalently attached to the TMR ligand (Fig. 2B), and the
amount of free TMR ligand in the medium was negligible after the
medium change. Further improvements will be needed to over-
come the following limitations in our system. First, there is a lim-
itation associated with the measurement of the in vivo Kd value for
binding on the membrane. As we mentioned above, FCCS mea-
surements of HRas and Raf binding on the membrane did not
provide accurate and reproducible results, possibly because of the
low diffusion constant, heterogeneous membrane structure, and
leakage of the fluorescence signal of Raf from the cytoplasm. Sec-
FIG 8 Effect of multivalent binding of Shc1 to pEGFR on EGFR-Ras-ERK signaling. (A) EGF-induced kinetics of phospho-EGFR (pEGFR), Ras-GTP,
phospho-MEK (pMEK), and phospho-ERK (pERK) were simulated in the models according to data shown in Fig. 6, without any corrections, and showed low
signal transmission from Ras-GTP in comparison to the experimental data. The experimental time courses of Ras-GTP and pTpY-ERK were obtained in our
previous studies (9, 22). The time courses of pEGFR and pMEK were quantified in this study (Fig. 7). (B) Three reactions involved in rate-limiting steps are
shown. (C) Heat map representing the logarithmic residual sum square values between the experiments and numerical simulations, which varied with respect to
both the dissociation constant and stoichiometry values of the reaction for Shc1-pEGFR binding. Blue indicates a better fit of the simulation to experiments. D
and E indicate parameter sets used in panels D and E (best fit), respectively. (D) After parameter corrections for MEK phosphorylation (B, middle) and ERK
phosphorylation (B, right), the EGF-induced kinetics of Ras-GTP, pMEK, and pERK were calculated with a stoichiometry value of 1.0 and fitted to experiments
by changing the dissociation constant value (B, left). The best-fit dissociation constant was 0.057 M. (E) EGF-induced kinetics of Ras-GTP, pMEK, and pERK
were calculated with a dissociation constant of 0.25M and the indicated stoichiometry values. (F to H) Multiple bindings of Shc to pEGFR. HeLa cells expressing
mEGFP, HaloTag, or both EGFR-mEGFP and HaloTag-Shc were cocultured at equal ratios. The boxed region in panel F is magnified in panel G. After incubation
with the TMR ligand and serum starvation for 1 h, the cells were stimulated with 10 ng/ml EGF for 15 min, followed by fixation. By FCS, the concentrations of
mEGFP and HaloTag-TMR were determined to be 2.5 M and 12 M, respectively. These values were used to calculate the ratio of HaloTag-Shc to EGFR-
mEGFP at each endosome in panel H (n 78 endosomes from 28 cells). Bars, 20 m (F) and 10 m (G).
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ond, the lower limit for the measurements of the in vivo Kd is also
problematic. In our experimental setup, we could not reproduc-
ibly calculate the in vivo Kd at values of 0.1 M. This was due
mainly to the sensitivity of fluorescence detection by imaging of
cells with low EGFP and HaloTag-TMR expression levels, in
which autofluorescence and substantial photobleaching inter-
fered with data acquisition. The third limitation concerns the
measurement of the in vivo Kd values in ternary protein com-
plexes. There are many scaffold proteins in the EGFR-Ras-ERK
MAP kinase pathway that regulate signaling efficiency and speci-
ficity (58–60). Measurements of the in vivo Kd values in ternary
protein complexes by FCCS will shed new light on how these
scaffold proteins regulate efficiency, specificity, and divergence in
the signaling pathway more quantitatively.
We established a method for measuring the in vivo Kd in living
cells by FCCS and quantified 20 in vivo Kd values for protein-
protein interactions involved in the EGFR-Ras-ERK MAP kinase
pathway in living HeLa cells. These in vivoKd values provide quan-
titative data that will help to elucidate various signaling pathways.
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